Charles River Laboratories International (CRL)
(Delayed Data from NYSE)
$166.91 USD
-2.73 (-1.61%)
Updated Aug 1, 2025 03:59 PM ET
After-Market: $166.81 -0.10 (-0.06%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth C Momentum A VGM
Key Expected Earnings Data
Report Date | Period Ending | Zacks Consensus Estimate | Earnings ESP |
---|---|---|---|
08/06/2025
Time: BMO |
6/2025 | $2.50 | 0.11% |
Earnings Summary
For their last quarter, Charles River Laboratories International (CRL) reported earnings of $2.34 per share, beating the Zacks Consensus Estimate of $2.06 per share. This reflects a positive earnings surprise of 13.59%. Look out for CRL's next earnings release on August 06, 2025. For the next earning release, we expect the company to report earnings of $2.50 per share, reflecting a year-over-year decrease of 10.71%.
Earnings History
Price & Consensus
Zacks News for CRL
Charles River Laboratories (CRL) Expected to Beat Earnings Estimates: Should You Buy?
CRL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Charles River Q2 Earnings Preview: What's in Store for the Stock?
Will Charles River (CRL) Beat Estimates Again in Its Next Earnings Report?
Is it Prudent to Retain Charles River Stock in Your Portfolio Now?
CRL FAQs
Charles River Laboratories International, Inc. (CRL) has announced they will report their next quarter earnings on August 06, 2025. For the next earning release, we expect the company to report earnings of $2.50 per share, reflecting a year-over-year decrease of -10.71%.
Charles River Laboratories International, Inc. has announced they will report their previous quarter earnings after the close of the market on August 06, 2025.
The Zacks Consensus Estimate for Charles River Laboratories International, Inc. (CRL) for the quarter ending in June 2025 is $2.50 a share. We expect Charles River Laboratories International, Inc. to miss by 0.11%.
In the earnings report for the quarter ending in June 2024, Charles River Laboratories International, Inc. (CRL) announced earnings of $2.80 per share versus the Zacks Consensus Estimate of $2.39 per share, representing a surprise of 17.15%.